



## Coronavirus Funding Opportunity Announcements

*Released by the GCO January - March 2022*

- [Coronavirus \(1/13/21\)](#)
- [Coronavirus \(2/1/21\)](#)
- [Coronavirus \(2/8/21\)](#)
- [Coronavirus \(2/14/21\)](#)
- [Coronavirus \(3/5/21\)](#)
- [Coronavirus \(3/8/21\)](#)
- [Coronavirus \(3/22/21\)](#)

---

**Sent:** Wednesday, January 13, 2021 6:12 AM

**Subject:** [GCO] COVID-19 Funding Opportunities (1/13/21)

**PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.**

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

**To automatically download images Add Sender to the Safe Senders List.**

## Research Services and Resources

Dear Research Community,

Below is a summary of COVID-19 funding opportunities recently released from the funding opportunity database SPIN. For more information about these opportunities, click [here](#).

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserve are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in [The Conduit newsletter](#).

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
091333	COVID-19 Research Grants	British Society for Antimicrobial Chemotherapy		18-Jan-2021 [LOI/Pre-App]	Not Specified
101184	COVID-19 Vaccine: Safety and Immunization Monitoring	Asian Development Bank		31-Jan-2021	50,000 USD
101316	Grand Challenges ICODA COVID-19 Data Science Grant Programme	Health Data Research UK		19-Jan-2021	100,000 USD
101255	Notice of Special Interest (NOSI): Availability of Emergency Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs	National Center for Advancing Translational Sciences/NIH/DHHS	NOT-TR-21-011	01-Jun-2021	60,000 USD
101425	Grand Challenge - COVID-19 Data Science Grants	International COVID-19 Data Alliance		19-Jan-2021	100,000 USD
101434	Future of Work at the Human-Technology Frontier: Core Research (FW-HTF)	National Science Foundation	21-548	23-Mar-2021	Not Specified
101494	Notice of Special Interest (NOSI): Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-21-012	05-Feb-2021	Not Specified
101368	Notice of Special Interest (NOSI): Administrative Supplements for COVID-19 Impacted NIMH Research	National Institute of Mental Health/NIH/DHHS	NOT-MH-21-120	01-Jun-2023	Not Specified
101488	RFA-FD-21-012 -- Physiologically Based Pharmacokinetic (PBPK) Models of Oral Absorption to Simulate the Results of Bioequivalence Studies (U01) Clinical Trials Optional	Food and Drug Administration/DHHS	RFA-FD-21-012	29-Jan-2021 [Optional] [LOI/Pre-App]	600,000 USD
096446	Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-243	02-Mar-2021	2,250,000 USD
100700	Notice of Special Interest (NOSI): Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp Clinical Trial Optional)	National Institutes of Health/DHHS	NOT-OD-21-020	05-Mar-2021	Not Specified

---

**Icahn School of Medicine at Mount Sinai**

1 Gustave L. Levy Place, New York  
NY 10029 United States

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
This is a broadcast email sent on behalf of the Sender and/or  
Department. If you wish to respond, please follow the contact  
instructions in the message ONLY.


---

**Sent:** Monday, February 1, 2021 11:00 AM  
**Subject:** [GCO] COVID-19 Funding Opportunities (2/1/21)

**PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.**

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

**To automatically download images Add Sender to the Safe Senders List.**



Dear Research Community,

Below is a summary of COVID-19 funding opportunities recently released from the National Institutes of Health.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in [The Conduit newsletter](#).

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office

**From:** Table of Contents for the NIH Guide for Grants & Contracts [<NIHTOC-L@LIST.NIH.GOV>](mailto:NIHTOC-L@LIST.NIH.GOV) **On Behalf Of** Guide TOC

**Sent:** Friday, January 29, 2021 3:00 PM

**To:** [NIHTOC-L@LIST.NIH.GOV](mailto:NIHTOC-L@LIST.NIH.GOV)

**Subject:** NIH Funding Opportunities and Notices for 01-29-2021 (The NIH Guide TOC)

**USE CAUTION: External Message.**



## NIH Guide for Grants and Contracts ([Web Version](#))

### Weekly NIH Funding Opportunities and Notices for January 29, 2021

#### General Notices

##### Notice of Changes to Funding Opportunities

- [Notice of NIDA's Participation in NOT- MD-21-008 "Notice of Special Interest \(NOSI\): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities"](#)

(NOT-DA-22-015)

National Institute on Drug Abuse

##### Notices of Intent to Publish

- [Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use \(R01 Clinical Trials Not Allowed\)](#)

(NOT-AA-21-001)

National Institute on Alcohol Abuse and Alcoholism

- [Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use \(R03 Clinical Trials Not Allowed\)](#)

(NOT-AA-21-002)

National Institute on Alcohol Abuse and Alcoholism

- [Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use \(R21 Clinical Trials Not Allowed\)](#)

(NOT-AA-21-003)

National Institute on Alcohol Abuse and Alcoholism

##### Notices of Special Interest

- [Notice of Special Interest \(NOSI\): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 \(COVID-19\)](#)

(NOT-AG-21-015)

National Institute on Aging

- [Notice of Special Interest \(NOSI\): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 \(COVID-19\)](#)

(NOT-DE-21-001)

National Institute of Dental and Craniofacial Research

NIH Funding Opportunities now available in RSS (Really Simple News Syndication) format - see [https://grants.nih.gov/grants/guide/rss\\_info.htm](https://grants.nih.gov/grants/guide/rss_info.htm) for details.



To UnSubscribe from the NIH Guide Weekly TOC LISTSERV, follow the instructions at <https://grants.nih.gov/grants/guide/listserv.htm>

**Icahn School of Medicine at Mount Sinai**

1 Gustave L. Levy Place, New York  
NY 10029 United States

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
This is a broadcast email sent on behalf of the Sender and/or  
Department. If you wish to respond, please follow the contact  
instructions in the message ONLY.

**From:** [research.listserv@mssm.edu](mailto:research.listserv@mssm.edu)  
**Subject:** [GCO] COVID-19 Funding Opportunities (2/8/21)  
**Date:** Monday, February 8, 2021 6:51:06 AM

---

**PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.**

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

**To automatically download images Add Sender to the Safe Senders List.**

Research Services and Resources



---

Dear Research Community,

Below are COVID-19 funding opportunities recently released from the National Institutes of Health (NIH), the funding opportunity database SPIN, and other funding opportunities sent to the Grants and Contracts Office (GCO).

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserve are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in [The Conduit newsletter](#).

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office

**From:** Table of Contents for the NIH Guide for Grants & Contracts [<nihtoc-l@list.nih.gov>](mailto:nihtoc-l@list.nih.gov)  
**On Behalf Of** Guide TOC  
**Sent:** Friday, February 5, 2021 3:01 PM  
**To:** [NIHTOC-L@LIST.NIH.GOV](mailto:NIHTOC-L@LIST.NIH.GOV)  
**Subject:** NIH Funding Opportunities and Notices for 02-05-2021 (The NIH Guide [TOC](#))  
[</nihtoc-l@list.nih.gov>](mailto:nihtoc-l@list.nih.gov)

**USE CAUTION: External Message.**



## NIH Guide for Grants and Contracts ([Web Version](#))

### Weekly NIH Funding Opportunities and Notices for February 5, 2021


#### Notices of Special Interest

- [Notice of Special Interest \(NOSI\): Complement in Basic Immunology \(CIBI\)](#)  
(NOT-AI-21-008) National Institute of Allergy and Infectious Diseases
- [Notice of Special Interest \(NOSI\): Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control](#)  
(NOT-CA-21-033) National Cancer Institute

- [Notice of Special Interest \(NOSI\): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19](#) (NOT-DA-21-017) National Institute on Drug Abuse
- [Notice of Special Interest \(NOSI\): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders](#) (NOT-DA-21-018) National Institute on Drug Abuse
- [Notice of Special Interest \(NOSI\): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19](#) (NOT-DA-21-017) National Institute on Drug Abuse
- [SARS-CoV-2, COVID-19 and Consequences of Alcohol Use \(R01 Clinical Trial Not Allowed\)](#) (RFA-AA-21-002) National Institute on Alcohol Abuse and Alcoholism  
Application Receipt Date(s): April 14, 2021
- [SARS-CoV-2, COVID-19 and Consequences of Alcohol Use \(R03 Clinical Trial Not Allowed\)](#) (RFA-AA-21-003) National Institute on Alcohol Abuse and Alcoholism  
Application Receipt Date(s): April 14, 2021
- [SARS-CoV-2, COVID-19 and Consequences of Alcohol Use \(R21 Clinical Trial Not Allowed\)](#) (RFA-AA-21-004) National Institute on Alcohol Abuse and Alcoholism  
Application Receipt Date(s): April 14, 2021

NIH Funding Opportunities now available in RSS (Really Simple News Syndication) format - see [https://grants.nih.gov/grants/guide/rss\\_info.htm](https://grants.nih.gov/grants/guide/rss_info.htm) for details.

To UnSubscribe from the NIH Guide Weekly TOC LISTSERV, follow the instructions at <https://grants.nih.gov/grants/guide/listserv.htm>



For more information about the SPIN opportunities, click here. A summary is below.

SPIN ID	Program Title	Sponsor Name	Sponsor Deadline		Funding
			Number	Date	Amount
066680	<a href="#">Prize in Medicine and</a>	Albany Medical Center		26-Mar-	500,000

## Biomedical Research

2021 USD

Contact Name

Contact Telephone [518-262-8137](tel:518-262-8137)Contact Email [AMCprize@mail.amc.edu](mailto:AMCprize@mail.amc.edu)Sponsor Website [Link to sponsor website](#)Program URL [Link to program URL](#)

Deadline Dates (ALL) 26-Mar-2021

Synopsis The Albany Medical Center Prize in Medicine and Biomedical Research recognizes, encourages and supports extraordinary and sustained contributions to improved health care and innovative biomedical research that demonstrably facilitates improvements in patient care. Given annually, the \$500,000 Prize is one of the largest awards in medicine and biomedical research in the United States.

075849 [Quality of Life Grants](#) Reeve (Christopher and Dana) Foundation 16-Mar-2021 50,000 USD

Contact Name

Contact Telephone [800-539-7309](tel:800-539-7309)Contact Email [Information@ChristopherReeve.org](mailto:Information@ChristopherReeve.org)Sponsor Website [Link to sponsor website](#)Program URL [Link to program URL](#)

Deadline Dates (ALL) 16-Mar-2021

Synopsis The Reeve Foundation awards Quality of Life grants to organizations that provide services to individuals with paralysis.

098158 [RFA-HD-21-023 -- NICHD Program](#) National Institute of Child Health and Human Development/NIH/DHHS 023 [Project Grants for HIV Research \(P01 Clinical Trial Optional\)](#) RFA- HD-21- [Optional] [LOI/Pre-App] 01-Mar-2021 1,000,000 USD

Contact Name Denise Russo, PhD

Contact Telephone [301-435-6871](tel:301-435-6871)Contact Email [denise.russo@mail.nih.gov](mailto:denise.russo@mail.nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 01-Mar-2021 [Optional][LOI/Pre-App], 31-Mar-2021

This Funding Opportunity Announcement (FOA) invites submission of Program Project (P01) applications to support

Synopsis integrated, multi-project research programs that address HIV scientific areas relevant to the NICHD mission as a well-defined, central research focus or objective.

[Notice of Special Interest \(NOSI\): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities](#)

101245 National Institutes of Health/DHHS NOT-MD-21-008 07-May-2021 Not Specified

Contact Name Deborah E. Linares, Ph.D., M.A.  
 Contact Telephone [301-402-2516](tel:301-402-2516)  
 Contact Email [deborah.linares@nih.gov](mailto:deborah.linares@nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)

Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022

This Notice of Special Interest (NOSI) highlights the need for research strategies and interventions to address vaccine hesitancy, uptake, and implementation among populations who experience health disparities in the US.\* Research is needed to understand and address misinformation, distrust, and hesitancy regarding vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), and herpes zoster) among adults in the United States and territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities and chronic medical conditions. The purpose of this NOSI is to solicit community-engaged research to: 1) evaluate intervention strategies (e.g., expand reach, access) to facilitate vaccination uptake in clinical and community contexts; and 2) address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations at high risk and likely to experience vaccine hesitancy.

[Notice of Special Interest \(NOSI\): Effects](#)

NOT-

101829 [of Smoking and Vaping on the Risk and Outcome of COVID-19 Infection](#) National Institute on Drug Abuse/NIH/DHHS DA-21-011 05-Jun-2021 Not Specified

Contact Name Raul Mandler, MD; FAAN; FANA

Contact Telephone [301-480-2541](tel:301-480-2541)

Contact Email [mandlerr@nih.gov](mailto:mandlerr@nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024

Synopsis The purpose of this notice is to communicate NIDA's interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection. This Notice is a reissuance of NOT-DA-20-084.

## Other FOAs sent to the GCO



[COVID-19 and Emerging Respiratory Viruses Research Award:](#)  
\$100,000 per year for up to two years

Timeline of grant process:

- **February 18, 2021:** Letters of Intent (LOIs) are due
- **March 1, 2021:** LOI Results. [proposalCENTRAL](#) opens to invited applicants
- **April 30, 2021:** Application deadline is April 30, 2021, 11:59 PM, ET)
- **June 30, 2021:** Outcome notifications are sent to all applicants

The Lung Association is proud to support the best and brightest minds in lung health research, and we encourage you to share this information with interested researchers seeking funding. Please [contact us](#) if you have questions.

**Icahn School of Medicine at Mount Sinai**

1 Gustave L. Levy Place, New York  
NY 10029 United States

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
This is a broadcast email sent on behalf of the Sender and/or  
Department. If you wish to respond, please follow the contact  
instructions in the message ONLY.



**From:** [research.listserv@mssm.edu](mailto:research.listserv@mssm.edu)

**Subject:** [GCO] COVID-19 Funding Opportunities (2/14/21) (NIH Notice of Intent to Publish 3 ROAs)  
**Date:** Sunday, February 14, 2021 7:07:30 AM

---

**PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.**

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

**To automatically download images Add Sender to the Safe Senders List.**

Research Services and Resources



---

Dear Research Community,

Below are three post-COVID Research Opportunity Announcements (ROAs) coming soon with short turn around from the National Institutes of Health (NIH). The initial ROAs are expected to be published by mid-February 2021. Initial awards are anticipated to be made in early March 2021.

Previous COVID-19 funding opportunities that have been circulated via the listserve are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in [The Conduit newsletter](#).

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office



<https://covid19.nih.gov/sites/default/files/2021-02/PASC-Pre-Notice.pdf>

Notice of Intent to Publish Research Opportunity Announcements (OTA-21-015) for the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Initiative

### **Purpose**

This Notice is to alert the community that NIH plans to publish Research Opportunity Announcements (ROAs) as part of the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) initiative. The solicited research will improve understanding of and develop strategies to prevent and treat post-acute manifestations of SARS-CoV-2 infection across the lifespan. The initial ROAs are expected to be published by mid-February 2021. Projects will be funded utilizing NIH's Other Transaction Authority (OTA), which offers flexibility and the ability to engage partners in collaborative innovation and problem solving. Initial awards are anticipated to be made in early March 2021.

This Notice is being provided for informational purposes to allow potential applicants additional time to develop responsive applications. NIH reserves the right to modify the scope and objectives as described in this Notice. Final scope, objectives, and requirements will be set forth in the published ROAs.

### **Background**

Some COVID-19 survivors report experiencing symptoms beyond the usual recovery time from the infection. In some cases, new symptoms and findings are reported that appear

linked to the timing of acute infection but emerge subsequently and evolve over time. Reported symptoms range from mild to incapacitating and can persist for months following acute disease. These symptoms and findings (i.e., post-acute sequelae) are reported in different organs and systems and can adversely affect overall quality of life. The magnitude of the public health impact of these sequelae is currently unknown but potentially profound, given the numbers of individuals across the age spectrum who have been and will be infected with SARS-CoV-2, the virus that causes COVID-19. It is a public health priority to understand and develop strategies to prevent and treat PASC.

### **Research Initiative Details**

The goal of the PASC Initiative is to systematically advance our understanding of the recovery process after SARS-CoV-2 infection and to prevent and treat PASC. Toward these ends, the overall PASC Initiative is designed to address three fundamental scientific questions:

- What is the biologic basis of the heterogeneity in recovery from SARS-CoV-2 infection?
- For those patients who do not fully recover or develop new symptoms/sequelae, what is the incidence/prevalence, clinical spectrum, and underlying biology?
- What interventions might improve recovery after SARS-CoV-2 infection and prevent long-term disability due to PASC?

In implementing the PASC initiative, NIH will solicit research proposals to understand recovery after SARS-CoV-2 infection and PASC. The PASC initiative will leverage a variety of platforms, including large and long-standing longitudinal studies; large-scale EHR/health systems-based cohort studies; COVID-19 clinical trials/networks; and COVID-19 registries, observational and clinical studies. These will be augmented by utilization of mobile and digital health strategies for patient recruitment, data collection, and follow-up. Applicants will be encouraged to leverage multidisciplinary teams to generate the critical data necessary to rapidly enhance understanding of PASC, including its epidemiology, risk factors for illness severity and outcomes, natural history, and pathophysiology.

Exploratory clinical trials testing strategies to treat symptoms and prevent progression of SARS-CoV-2 infection to PASC are also an important part of this initiative and will be the subject of subsequent solicitations.

Together, these activities will constitute a rigorous and comprehensive research program on PASC across the spectrum of COVID-19 clinical presentation, across diverse populations, and throughout the lifespan, leading to findings and innovative treatment and preventive strategies that are applicable to all who are affected, including populations that bear a disproportionate burden of SARS-CoV-2 infection. NIH intends for projects funded under this program to be part of a coordinated Consortium that will collectively pursue the goal of understanding, treating, and preventing PASC by collaboratively developing common protocol elements; adopting common data elements; and sharing data, biospecimens, and knowledge within the Consortium and with the broader research community.

Toward these ends, NIH plans initially to publish three ROAs to solicit applications for:

## ROA #1

**Clinical Research Studies** targeting three domains: (a) Clinical Case-Based Recovery Meta- Cohort, (b) Autopsy Studies, and (c) EHR-/Health Systems-Based Analyses. Applications for this ROA may encompass one or more of these three domains.

### a. **Clinical Case-Based Recovery Meta-Cohort**

At the heart of the PASC Initiative is the SARS-CoV-2 Recovery Cohort, a collaborative meta-cohort that will leverage ongoing fit-for-purpose cohorts as well as new cohorts to facilitate the rapid launch of multi-disciplinary observational and mechanistic research on the incidence, risk factors, and mechanisms involved in PASC morbidity. This meta-cohort will bring together clinical cohorts of research participants across the lifespan with a history of SARS-CoV-2 infection, COVID-19, and/or PASC across the lifespan, of two main types:

1. *Acute*. Cohort studies with well-characterized pre-infection and/or acute infection baseline data and established plans for continued follow-up from the acute infection to understand the natural history and underlying biology of the heterogeneous recovery after SARS-CoV-2 infection.
2. *Post-acute*. Cohort studies of the post-acute phase enrolling participants with SARS-CoV-2 infection, COVID-19, or PASC with appropriate comparison participants and conducting intensive investigation of relevant organ injury and other system dysfunction and continued longitudinal follow-up of health outcomes.

The studies funded will constitute a meta-cohort encompassing inclusive participation reflective of appropriate diversity and enrolling adults and children. For the purposes of studies of adults, NIH anticipates assembling from across all the contributing cohorts a total of at least 20,000 cases of SARS-CoV-2 infection/COVID-19 cases and at least 1,000 PASC cases. For the purposes of studies of children, we anticipate assembling from across the contributing cohorts a total of at least 10,000 cases of SARS-CoV-2 infection/COVID-19 cases and at least 500 PASC cases. Preference may be given to applicants capable of studying large numbers of cases and appropriate comparison participants; this will be further detailed in the ROA. Applicants proposing smaller samples will be expected to provide strong justification for their approach based on

other considerations, e.g., special population characteristics or deep pre-infection phenotyping, special investigations of specific organ dysfunction, etc.

**b. Autopsy Studies:** The goal of this effort is to provide in-depth histopathologic analysis of a broad range of organs and tissues in order to identify injury due to SARS-CoV-2 infection and/or its sequelae that lead to or contribute to PASC. Investigators will be expected to submit tissues to a biobank for distribution across the Consortium and more broadly with the research community.

**c. EHR-/Health Systems-Based Studies:** The goal of this effort is to advance the understanding and management of the post-acute effects of COVID-19 across the lifespan by: making innovative use of real world data such as electronic health records, health

systems data, and other large data sets; by further expanding capabilities of existing data resources; leveraging health-systems based protocols to inform PASC clinical characterization through patient survey-based symptom reporting; and by working in an integrated fashion with other components of the coordinated NIH response to address PASC.

## **ROA #2**

**Clinical Science Core**, for which applicants will be expected to:

- Foster collaboration across the Consortium; coordinate and provide logistical support

(scheduling, meetings, communication platforms) for the PASC investigator consortium and all relevant working groups/committees, including platforms to solicit and incorporate patient viewpoints; facilitate use of toolkits of common data elements, surveys/questionnaires, and mobile health tools; incorporate use of various consent processes (e.g., e-consent) as applicable; interface with IRBs; and support the literature review in PASC.

- Provide expertise and statistical input on clinical study design, implementation, execution, and monitoring, including advising and coordinating the development and implementation of protocols/sub-study protocols; develop manual of procedures, case report forms, identification and selection of surveys and questionnaires, and recruitment strategies to promote inclusive participation; assure delivery of high-quality data, including mobile data, to the Data Resource Core; and develop monitoring procedures for study performance and safety.
- Support and provide expertise in clinical research study data management, data quality control, study monitoring, statistical analyses, sample size calculations, data reports for oversight and monitoring boards and regulatory entities, analysis expertise and support for phenotyping in adults and children, including the acute and post-acute manifestations, at a clinical and biological level.
- Provide framework/infrastructure and statistical expertise for results analysis, interpretation and dissemination, and development of final phenotype characterization and diagnostic algorithms.
- Coordinate receipt of the collection, analysis, deposition, and central management of patient biospecimens, transfer to the PASC biorepository (to be identified by NIH at a later date), and linkage of these biospecimens to clinical data in order to provide critical tools and resources for future PASC research.

<page3image3184418016.png></page3image3184418016.png>

## **ROA #3**

**Data Resource Core**, for which applicants will be expected to:

Facilitate the standardized collection of clinical data (i.e., usage of common data elements) and data harmonization, assist research projects with linking these data with other data, including but not limited to: publicly available sources (e.g., Census data, Area

Deprivation Index, etc.), electronic health records (EHR) and others as needed, as well as perform quality control, data curation, and analyses, and provide data informatics tools.

- Maximize the value of the collective data sets and enable interoperability with other NIH COVID-19 research resources by supporting studies with a cloud-based data “workbench;” promoting adoption of common data elements and harmonized definitions of key variables; and facilitating seamless integration into existing large-scale well-curated genotypic and phenotypic data sets.
- Create a data coordination and analytics framework to compile and link data from extant clinical studies/networks, biosamples, imaging, EHR and related records data, mobile health data and other non-traditional data sources; and provide access to datasets for analysis by the research community.

Additional ROAs may be issued in the future as needed.

Researchers planning to apply are strongly encouraged to read all three of these interrelated research opportunities when they are published.

Inquiries

Please direct all inquiries to: [NHLBI\\_OTA@mail.nih.gov](mailto:NHLBI_OTA@mail.nih.gov)

**Icahn School of Medicine at Mount Sinai**

1 Gustave L. Levy Place, New York  
NY 10029 United States

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
This is a broadcast email sent on behalf of the Sender and/or  
Department. If you wish to respond, please follow the contact  
instructions in the message ONLY.

**From:** [research.listserv@mssm.edu](mailto:research.listserv@mssm.edu)  
**Subject:** [GCO] COVID-19 Funding Opportunities (3/5/21)  
**Date:** Wednesday, March 3, 2021 3:24:45 PM

---

**PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.**

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

**To automatically download images Add Sender to the Safe Senders List.**

## Research Services and Resources



Dear Research Community,

Below is a summary of COVID-19 funding opportunities recently released from the funding opportunity database SPIN. For more information on the SPIN FOAs, click [here](#).

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserve are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in [The Conduit newsletter](#).

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office



For more information about the SPIN opportunities, click [here](#). A summary is below.

<b>SPIN ID</b>	<b>Program Title</b>	<b>Sponsor Name</b>	<b>Sponsor Number</b>	<b>Deadline Date</b>	<b>Funding Amount</b>
000548	Trustee (Research) Grants	Sage (Russell) Foundation		04-May-2021	175,000 USD
088268	Assessment of Prevention, Diagnosis, and Treatment Options Program	Patient-Centered Outcomes Research Institute (PCORI)		01-Jun-2021	5,000,000 USD
098066	Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-20-065	14-Mar-2021	Not Specified



	Vaccine Candidates Against SARS- CoV-2 RFA-DA-21-020 -- HEAL Initiative: HEALthy Brain and Child Development National Institutes of Health/DHHS		RFA-DA- 21-020	31-Mar- 2021	Not Specified
101558	Study (Collaborative U01- Clinical Trial Not Allowed)				
	RFA-DA-21-021 -- HEAL Initiative: HEALthy Brain and Child Development National Institutes of Health/DHHS		RFA-DA- 21-021	31-Mar- 2021	Not Specified
101561	Study (U01 - Clinical Trial Not Allowed)				
	RFA-DA-21-022 -- HEAL Initiative: HEALthy Brain and Child Development Consortium Administrative Core (U24 - Clinical Trial Not Allowed)		RFA-DA- 21-022	31-Mar- 2021	Not Specified
101569					
	RFA-DA-21-023 -- HEAL Initiative: HEALthy Brain and Child Development Health/DHHS Data Coordinating Center (U24) Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and		RFA-DA- 21-023	31-Mar- 2021	Not Specified
101570					
	National Institute on Drug Abuse/NIH/DHHS		NOT-DA- 21-019	07-May- 2021	Not Specified
102120					

	Substance Use Disorders				
	Simons Foundation Autism Research Initiative				
102283	(SFARI) - Maternal Simons Foundation COVID-19 Request for Applications Joint Program Committee 6 (JPC-6)/Combat			12-Mar-2021	Not Specified
102441	Casualty Care Research Program (CCCRP)--En Route Care Award Notice of Special Interest (NOSI): Neurological and Neurocognitive	Department of the Army	W81XWH-21-	31-Mar-2021	Not Specified
			DMRDP-ERCA	[LOI/Pre-App]	
102443	Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration	National Institute on Aging/NIH/DHHS	NOT-AG-21-016	05-Jun-2021	Not Specified

**Icahn School of Medicine at Mount Sinai**

1 Gustave L. Levy Place, New York  
NY 10029 United States

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.



**From:** [research.listserv@mssm.edu](mailto:research.listserv@mssm.edu)  
**Subject:** [GCO] COVID-19 Funding Opportunities (3/8/21)  
**Date:** Monday, March 8, 2021 3:58:37 PM

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

To automatically download images Add Sender to the Safe Senders List.

### Research Services and Resources



Dear Research Community,

Below are COVID-19 funding opportunities recently released from the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in [The Conduit newsletter](#).

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102483	<a href="#">Notice of Special Interest (NOSI): Urgent Competitive Revisions to IDeA and NARCH Programs to Address SARS-CoV-2 Vaccine Hesitancy</a>	National Institute of General Medical Sciences/NIH/DHHS	NOT-GM-21-021	30-Apr-2021	200,000 USD

Contact Name	Sheila A. Caldwell, Ph.D.		
Contact Telephone			
Contact Email	<a href="mailto:caldwells@mail.nih.gov">caldwells@mail.nih.gov</a>		
Sponsor Website			
Program URL	<a href="#">Link to program URL</a>		
Deadline Dates (ALL)	30-Apr-2021		
Synopsis	The National Institute of General Medical Sciences (NIGMS) announces the availability of urgent competitive revisions to support vaccine hesitancy research relevant to SARS-CoV-2. This NOSI is intended to provide funds for the Institutional Development Award (IDeA) (P20, P30, and U54) and Native American Research Centers for Health (NARCH) (S06) grantees to expand the scope of their active grants.		
102533	<a href="#">Special Emphasis Notice (SEN): AHRQ Announces Interest in Health Services Research to Address Substance Use Disorder Epidemic</a>	Agency for Healthcare Research and Quality/DHHS	NOT-HS-21-010 15-Mar-2023 Not Specified
Contact Name	Sebastian Tong, MD, MPH		
Contact Telephone			
Contact Email	<a href="mailto:Sebastian.Ton@ahrq.hhs.gov">Sebastian.Ton@ahrq.hhs.gov</a>		
Sponsor Website			
Program URL	<a href="#">Link to program URL</a>		
Deadline Dates (ALL)	15-Mar-2023		
Synopsis	The purpose of this Special Emphasis Notice (SEN) is to inform the research community that the Agency for Healthcare Research and Quality is interested in receiving health services research grant applications to advance our nation's understanding of the substance use disorder crisis and provide solutions for addressing it.		
102547	<a href="#">Medical Education Grants: Closing Knowledge Gaps in Osteoarthritis and Osteoarthritis Pain</a>	Pfizer Pharmaceuticals	19-Mar-2021 200,000 USD
Contact Name	Jessica Romano		
Contact Telephone	<a href="tel:212-733-2323">212-733-2323</a>		
Contact Email	<a href="mailto:jessica.romano@pfizer.com">jessica.romano@pfizer.com</a>		
Sponsor Website	<a href="#">Link to sponsor website</a>		
Program URL	<a href="#">Link to program URL</a>		
Deadline Dates (ALL)	19-Mar-2021 , 18-Jun-2021 , 20-Aug-2021		
Synopsis	Pfizer is issuing this Request for Proposals (RFP) to support virtual and potentially live programs and other innovative digital medical education for HCPs. The typical grant maximum under this RFP will be up to \$200,000.		

**Icahn School of Medicine at Mount Sinai**  
1 Gustave L. Levy Place, New York  
NY 10029 United States

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
This is a broadcast email sent on behalf of the Sender and/or  
Department. If you wish to respond, please follow the contact  
instructions in the message ONLY.

**From:** [research.listserv@mssm.edu](mailto:research.listserv@mssm.edu)  
**Subject:** [GCO] COVID-19 Funding Opportunities (3/22/21)  
**Date:** Monday, March 22, 2021 6:24:53 AM

[View in browser](#)

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

To automatically download images Add Sender to the Safe Senders List.

### Research Services and Resources



Dear Research Community,

Below are COVID-19 funding opportunities recently released from the funding opportunity database SPIN and other announcements sent to the GCO.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in [The Conduit newsletter](#).

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office



SPIN ID	Program Title	Sponsor Name	Sponsor Deadline Number Date	Funding Amount
091946	<a href="#">COVID-19 HPC Consortium</a>	Extreme Science and Engineering Discovery	Continuous	Not Submission Specified

Environment (XSEDE)

Contact Name  
 Contact Telephone  
 Contact Email [info@xsede.org](mailto:info@xsede.org)  
 Sponsor Website [Link to sponsor website](#)  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL)

Synopsis  
 The COVID-19 HPC Consortium encompasses computing capabilities from some of the most powerful and advanced computers in the world. XSEDE hopes to empower researchers around the world to accelerate understanding of the COVID-19 virus and the development of treatments and vaccines to help address infections. Consortium members manage a range of computing capabilities that span from small clusters to some of the very largest supercomputers in the world.

[Notice of Special Interest \(NOSI\): Urgent Competitive Revisions to IDeA and NARCH Programs for SARS-CoV-2 Surveillance Studies](#) National Institute of General Medical Sciences/NIH/DHHS NOT-GM-21-031 31-Mar-2021 Not Specified

Contact Name Hongwei Gao, M.D., Ph.D.  
 Contact Telephone  
 Contact Email [hongwei.gao@nih.gov](mailto:hongwei.gao@nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 31-Mar-2021

Synopsis  
 The National Institute of General Medical Sciences (NIGMS) announces the availability of funds to supplement active Institutional Development Award (IDeA, P20, P30, and U54) and Native American Research Centers for Health (NARCH) (S06) awards for surveillance studies of SARS-CoV-2 viral strains.

[Notice of Special Interest \(NOSI\): Administrative Supplements and Urgent Competitive Revisions for NIH Grants to Add or Expand Research Focused on Maternal Health, Structural Racism and Discrimination, and COVID-19](#) Office of the Director, National Institutes of Health/NIH/DHHS NOT-OD-21-071 14-Apr-2021 2,000,000 USD

Contact Name  
 Contact Telephone  
 Contact Email [IMPROVEinitiative@od.nih.gov](mailto:IMPROVEinitiative@od.nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 14-Apr-2021

Synopsis  
 The Office of the Director of the National Institutes of Health (NIH), on behalf of the NIH Maternal Mortality Task Force, announces the opportunity for investigators with relevant active NIH-supported grants to address the following scientific priorities for Implementing a Maternal health and PRenancy Outcomes Vision for Everyone (IMPROVE) in the context of the ongoing COVID-19 pandemic for pregnant persons and up to one year postpartum:  
 Understand the effects of SARS-CoV-2 infection and the COVID-19 pandemic on maternal mental health, well-being, functioning and quality of life  
 Identify psychosocial and behavioral health risk factors related to the COVID-19 pandemic that affect maternal mental health and functioning outcomes  
 Address the impact of structural racism and discrimination (SRD) on maternal health outcomes in the context of COVID-19

[Notice of Special Interest \(NOSI\): Impact of COVID-19 on Dementia Risk, Progression and Outcomes in ADRD Populations](#) National Institute of Neurological Disorders and Stroke/NIH/DHHS NOT-NS-21-037 05-May-2021 1,332,000 USD

Contact Name Dr. Debra Babcock  
 Contact Telephone [301-496-9964](tel:301-496-9964)  
 Contact Email [dbabcock@ninds.nih.gov](mailto:dbabcock@ninds.nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 05-May-2021

Synopsis  
 NINDS is interested in applications for supplements to human subjects awards administered by the NINDS to conduct research on the effects of COVID-19 on the development of, or disease progression in, Alzheimer's Disease-Related Dementias (ADRDs). ADRDs include Frontotemporal Degeneration (FTD), Lewy Body Dementia (LBD), Vascular contributions to Cognitive Impairment and Dementia (VCID), and Mixed Etiology Dementias (MED).

## Other Funding Opportunity Announcements

SOLVE ME/CFS INITIATIVE

### THE RAMSAY GRANT PROGRAM

Solve M.E. will accept applications to study ME/CFS and Long-Covid from February 22– April 30, 2021

Through the Ramsay Program, Solve M.E. invests in research studies in ME/CFS or long-COVID with a particular emphasis on engaging young investigators and researchers new to the field. Collaborative proposals (involving 2 or more research groups) and studies that examine the similarities and differences between ME/CFS and long-COVID are encouraged.

Click [here](#) for more information.

**Icahn School of Medicine at Mount Sinai**

1 Gustave L. Levy Place, New York  
NY 10029 United States

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
This is a broadcast email sent on behalf of the Sender and/or  
Department. If you wish to respond, please follow the contact  
instructions in the message ONLY.